NIAID Strategic Plan for Tuberculosis Research, 2024 Update

Scanning electron micrograph of Mycobacterium tuberculosis bacteria colorized in blue on a black background.

NIAID Strategic Plan for Tuberculosis Research, 2024 Update

Tuberculosis is the second leading infectious cause of death worldwide. In the updated strategic plan, NIAID details four strategic priorities that are critical to the development and evaluation of the knowledge and tools needed to end TB globally. 

World TB Day 2024 – Yes! We Can End TB!

In observance of World Tuberculosis Day (Sunday, March 24), NIAID joins our partners in reaffirming our commitment to ending the tuberculosis (TB) pandemic while honoring the lives lost to TB disease.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Grant for Research into Highly Deadly Variant of Tuberculosis

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.radboudumc.nl/en/news-items/2024/grant-for-research-into-highly-deadly-variant-of-tuberculosis
Research Institution
Radboud University Medical Center
Short Title
Grant for Research into Highly Deadly Variant of Tuberculosis
Content Coordinator
Claudia Wair

Drug-Resistant Tuberculosis Responds Rapidly to Bedaquiline-Based Second-Line Therapy

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.weill.cornell.edu/news/2024/02/drug-resistant-tuberculosis-responds-rapidly-to-bedaquiline-based-second-line-therapy
Research Institution
Weill Cornell Medicine
Short Title
Drug-Resistant Tuberculosis Responds Rapidly to Bedaquiline-Based Second-Line Therapy
Content Coordinator
Claudia Wair

Sangmi Oh, Ph.D.

Section or Unit Name
Tuberculosis Research Section
Exclude from directory
Off
Section/Unit: Location
NIH Main Campus, Bethesda, MD
This Researcher/Clinician’s Person Page
Sangmi Oh, Ph.D.
Parent Lab/Program
Laboratory of Clinical Immunology and Microbiology
Program Description

The Tuberculosis Research Section (TBRS) is a multidisciplinary group of research scientists composed of biologists, chemists, and clinical researchers who share a common interest in TB drug discovery. Dr. Sangmi Oh is in charge of the chemistry part of TBRS, focusing on medicinal chemistry for the development of novel antitubercular agents and making diverse chemical probes for an in-depth understanding of bacterial bugs.

Selected Publications

Yadav VD, Boshoff HI, Trifonov L, Roma JSO, Ioerger TR, Barry CE 3rd, Oh S. Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents. ACS Med Chem Lett. 2023 Aug 15;14(9):1275-1283.

Finin P, Khan RMN, Oh S, Boshoff HIM, Barry CE 3rd. Chemical approaches to unraveling the biology of mycobacteria. Cell Chem Biol. 2023 May 18;30(5):420-435.

Oh S, Libardo MDJ, Azeeza S, Pauly GT, Roma JSO, Sajid A, Tateishi Y, Duncombe C, Goodwin M, Ioerger TR, Wyatt PG, Ray PC, Gray DW, Boshoff HIM, Barry CE 3rd. Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. ACS Infect Dis. 2021 Feb 12;7(2):479-492.

Libardo MDJ, Duncombe CJ, Green SR, Wyatt PG, Thompson S, Ray PC, Ioerger TR, Oh S, Goodwin MB, Boshoff HIM, Barry CE 3rd. Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in drug metabolism and tryptophan biosynthesis. Cell Chem Biol. 2021 Aug 19;28(8):1180-1191.e20.

Oh S, Trifonov L, Yadav VD, Barry CE 3rd, Boshoff HI. Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets. Front Cell Infect Microbiol. 2021 Mar 15;11:611304.

Oh S, Park Y, Engelhart CA, Wallach JB, Schnappinger D, Arora K, Manikkam M, Gac B, Wang H, Murgolo N, Olsen DB, Goodwin M, Sutphin M, Weiner DM, Via LE, Boshoff HIM, Barry CE 3rd. Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase. J Med Chem. 2018 Nov 21;61(22):9952-9965. 

Visit PubMed for a full list of publications.

Major Areas of Research
  • Medicinal chemistry for tuberculosis drug discovery
  • Design and synthesis of chemical probes for the study of Mycobacterium tuberculosis
  • Synthetic approaches for the study of mechanism of action

NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins

A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The trial will include 330 participants aged 15 years and older who have or are likely to have TBM based on signs and symptoms, including people living with and without HIV. Because pregnant women are eligible to enroll in this study with appropriate consent, a small number of pregnant women are expected to be included.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Pranay Sinha, MD, Receives K01 Grant to Study How Nutrition Impacts TB Incidence, Mortality

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.bumc.bu.edu/camed/2023/11/30/pranay-sinha-md-receives-k01-grant-to-study-how-nutrition-impacts-tb-incidence-mortality/
Research Institution
Boston University
Short Title
Pranay Sinha, MD, Receives K01 Grant to Study How Nutrition Impacts TB Incidence, Mortality
Content Coordinator
Claudia Wair

To Build Better Tuberculosis Vaccines, Saint Louis University Researchers Develop a New Model by Leveraging an Old Vaccine

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.slu.edu/news/2023/november/new-model-for-tuberculosis-vaccine.php
Research Institution
Saint Louis University
Short Title
To Build Better Tuberculosis Vaccines, Saint Louis University Researchers Develop a New Model by Leveraging an Old Vaccine
Content Coordinator
Claudia Wair

ISB Researchers Find a Chink in the Armor of Tuberculosis Pathogen

National and Regional Biocontainment Research Facilities

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.  

Subscribe to Tuberculosis